Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis
Conclusion: Apatinib exhibited modest activity and acceptable toxicity for advanced NSCLC after the failure of chemotherapy or other targeted therapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Chengxi Yang Wen Feng Di Wu Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Hypertension | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Skin | Study | Toxicology